Harbour Biomed announced a collaboration with Bristol Myers Squibb to develop multispecific antibodies, receiving about $90 million up front and potential milestones that could exceed $1 billion. The partnership expands Harbour’s multispecific antibody programs and reflects continued Big Pharma appetite for multispecific platforms to address difficult oncology targets. The structure — near‑term cash plus large downstream milestones — mirrors recent dealmaking patterns in which large firms secure access to platform innovation while spreading development risk across partners.